1069 related articles for article (PubMed ID: 26014294)
1. BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small-Cell Lung Cancer.
Zhou C; Wu YL; Chen G; Liu X; Zhu Y; Lu S; Feng J; He J; Han B; Wang J; Jiang G; Hu C; Zhang H; Cheng G; Song X; Lu Y; Pan H; Zheng W; Yin AY
J Clin Oncol; 2015 Jul; 33(19):2197-204. PubMed ID: 26014294
[TBL] [Abstract][Full Text] [Related]
2. First-line penpulimab combined with paclitaxel and carboplatin for metastatic squamous non-small-cell lung cancer in China (AK105-302): a multicentre, randomised, double-blind, placebo-controlled phase 3 clinical trial.
Zhong H; Sun S; Chen J; Wang Z; Zhao Y; Zhang G; Chen G; Zhou M; Zhou J; Du Y; Wu L; Xu Z; Mei X; Zhang W; He J; Cui J; Zhang Z; Luo H; Liu W; Sun M; Wu J; Shen Y; Zhang S; Yang N; Wang M; Lu J; Li K; Yao W; Sun Q; Yue H; Wang L; Ye S; Li B; Zhuang X; Pan Y; Zhang M; Shu Y; He Z; Pan L; Ling Y; Liu S; Zhang Q; Jiao S; Han B
Lancet Respir Med; 2024 May; 12(5):355-365. PubMed ID: 38309287
[TBL] [Abstract][Full Text] [Related]
3. Phase II trial of carboplatin, paclitaxel, cetuximab, and bevacizumab followed by cetuximab and bevacizumab in advanced nonsquamous non-small-cell lung cancer: SWOG S0536.
Kim ES; Moon J; Herbst RS; Redman MW; Dakhil SR; Velasco MR; Hirsch FR; Mack PC; Kelly K; Heymach JV; Gandara DR
J Thorac Oncol; 2013 Dec; 8(12):1519-28. PubMed ID: 24189513
[TBL] [Abstract][Full Text] [Related]
4. Atezolizumab and Platinum Plus Pemetrexed With or Without Bevacizumab for Metastatic Nonsquamous Non-Small Cell Lung Cancer: A Phase 3 Randomized Clinical Trial.
Shiraishi Y; Kishimoto J; Sugawara S; Mizutani H; Daga H; Azuma K; Matsumoto H; Hataji O; Nishino K; Mori M; Shukuya T; Saito H; Tachihara M; Hayashi H; Tsuya A; Wakuda K; Yanagitani N; Sakamoto T; Miura S; Hata A; Okada M; Kozuki T; Sato Y; Harada T; Takayama K; Yamamoto N; Nakagawa K; Okamoto I
JAMA Oncol; 2024 Mar; 10(3):315-324. PubMed ID: 38127362
[TBL] [Abstract][Full Text] [Related]
5. Three-arm, randomized, phase 2 study of carboplatin and paclitaxel in combination with cetuximab, cixutumumab, or both for advanced non-small cell lung cancer (NSCLC) patients who will not receive bevacizumab-based therapy: An Eastern Cooperative Oncology Group (ECOG) study (E4508).
Hanna NH; Dahlberg SE; Kolesar JM; Aggarwal C; Hirsch FR; Ramalingam SS; Schiller JH
Cancer; 2015 Jul; 121(13):2253-61. PubMed ID: 25740387
[TBL] [Abstract][Full Text] [Related]
6. Phase 2 study of carboplatin, docetaxel, and bevacizumab as frontline treatment for advanced nonsmall-cell lung cancer.
William WN; Kies MS; Fossella FV; Liu DD; Gladish G; Tse WH; Lee JJ; Hong WK; Lippman SM; Kim ES
Cancer; 2010 May; 116(10):2401-8. PubMed ID: 20225327
[TBL] [Abstract][Full Text] [Related]
7. Phase III, Randomized Study of Atezolizumab Plus Bevacizumab and Chemotherapy in Patients With
Park S; Kim TM; Han JY; Lee GW; Shim BY; Lee YG; Kim SW; Kim IH; Lee S; Kim YJ; Park JH; Park SG; Lee KH; Kang EJ; Kim JW; Shin SH; Ock CY; Nam BH; Lee J; Jung HA; Sun JM; Lee SH; Ahn JS; Ahn MJ
J Clin Oncol; 2024 Apr; 42(11):1241-1251. PubMed ID: 37861993
[TBL] [Abstract][Full Text] [Related]
8. Phase-I/II study of bortezomib in combination with carboplatin and bevacizumab as first-line therapy in patients with advanced non-small-cell lung cancer.
Piperdi B; Walsh WV; Bradley K; Zhou Z; Bathini V; Hanrahan-Boshes M; Hutchinson L; Perez-Soler R
J Thorac Oncol; 2012 Jun; 7(6):1032-40. PubMed ID: 22534815
[TBL] [Abstract][Full Text] [Related]
9. Retrospective evaluation of the clinical and radiographic risk factors associated with severe pulmonary hemorrhage in first-line advanced, unresectable non-small-cell lung cancer treated with Carboplatin and Paclitaxel plus bevacizumab.
Sandler AB; Schiller JH; Gray R; Dimery I; Brahmer J; Samant M; Wang LI; Johnson DH
J Clin Oncol; 2009 Mar; 27(9):1405-12. PubMed ID: 19224857
[TBL] [Abstract][Full Text] [Related]
10. STAR-121: A Phase III Randomized Study of Domvanalimab and Zimberelimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Untreated Metastatic Non-Small Cell Lung Cancer With No Actionable Gene Alterations.
Rodriguez-Abreu D; Bosch-Barrera J; Gray JE; Ahn MJ; Johnson M; Yu X; Mohammad S; Chen X; Todd T; Kim J; Reck M
Clin Lung Cancer; 2024 May; 25(3):274-279. PubMed ID: 38310035
[TBL] [Abstract][Full Text] [Related]
11. Artemis: A Multicenter, Open-Label, Single-Arm, Phase II Study to Evaluate the Efficacy and Safety of First-Line Carboplatin/Paclitaxel/Lenvatinib/Pembrolizumab Combination for Previously Untreated Advanced or Recurrent Thymic Carcinomas.
Okuma Y; Nomura S; Sakakibara-Konishi J; Tsukita Y; Murakami S; Hosomi Y; Tambo Y; Kogure Y; Yoshioka H; Tamiya M; Ninomiya K; Iwama E
Clin Lung Cancer; 2024 Jun; 25(4):389-394. PubMed ID: 38413246
[TBL] [Abstract][Full Text] [Related]
12. Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab.
Gualberto A; Hixon ML; Karp DD; Li D; Green S; Dolled-Filhart M; Paz-Ares LG; Novello S; Blakely J; Langer CJ; Pollak MN
Br J Cancer; 2011 Jan; 104(1):68-74. PubMed ID: 21102589
[TBL] [Abstract][Full Text] [Related]
13. Myeloprotection with trilaciclib in Chinese patients with extensive-stage small cell lung cancer receiving chemotherapy: Results from a randomized, double-blind, placebo-controlled phase III study (TRACES).
Cheng Y; Wu L; Huang D; Wang Q; Fan Y; Zhang X; Fan H; Yao W; Liu B; Yu G; Pan Y; Xu F; He Z; Dong X; Ma R; Min X; Ge X; Chen H; Liu Q; Hu Y; Liu Y; Yang C; Yang Y; Li X; Zhou L
Lung Cancer; 2024 Feb; 188():107455. PubMed ID: 38224653
[TBL] [Abstract][Full Text] [Related]
14. Biosimilar candidate IBI305 plus paclitaxel/carboplatin for the treatment of non-squamous non-small cell lung cancer.
Yang Y; Wu B; Huang L; Shi M; Liu Y; Zhao Y; Wang L; Lu S; Chen G; Li B; Xie C; Fang J; Yang N; Zhang Y; Cui J; Song Y; Zhang C; Mei X; Cao B; Yang L; Cheng Y; Ying K; Sun T; Ren B; Yu Q; Liao Z; Pei Z; Wang M; Zhou J; Yu S; Feng G; Wan H; Wang H; Gao S; Wang J; An G; Geng Y; Ji Y; Yuan Y; Ma S; Jia Z; Hu M; Zhou H; Yu J; Sun X; Zhang L
Transl Lung Cancer Res; 2019 Dec; 8(6):989-999. PubMed ID: 32010577
[TBL] [Abstract][Full Text] [Related]
15. Could Jinfukang alleviate the chemotherapy-related adverse effects in non-small cell lung cancer patients?: A protocol for a double-blind, randomized controlled trial.
Zheng X; Wang W; Wang G; Liu S
Medicine (Baltimore); 2021 Jul; 100(28):e25002. PubMed ID: 34260519
[TBL] [Abstract][Full Text] [Related]
16. Comparison of Efficacy and Safety of a Bevacizumab Biosimilar, in Combination with Chemotherapies, in Nonresectable Metastatic Colorectal Cancer and in Advanced Nonsquamous Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Phase III Study.
Kasliwal S; K R; Reddy P; Maharaj N; M G; Adhav A; Harsh K; Madnoorkar N; Diwan A; Gupta M; Patel G; J SB; Dvorkin MV
South Asian J Cancer; 2024 Jan; 13(1):66-76. PubMed ID: 38721097
[TBL] [Abstract][Full Text] [Related]
17. First-Line Treatment with Bevacizumab and Platinum Doublet Combination in Non-Squamous Non-Small Cell Lung Cancer: A Retrospective Cohort Study in US Oncology Community Practices.
Lunacsek OE; Ravelo A; Coutinho AD; Hazard SJ; Green MR; Willey J; Eaddy M; Goertz HP
Drugs Real World Outcomes; 2016 Sep; 3(3):333-343. PubMed ID: 27747837
[TBL] [Abstract][Full Text] [Related]
18. A multicenter phase II study of Q3 week or weekly paclitaxel in combination with bevacizumab for the treatment of metastatic or unresectable angiosarcoma.
Bui N; Kamat N; Ravi V; Chawla S; Lohman M; Ganjoo KN
Rare Tumors; 2018; 10():2036361318771771. PubMed ID: 29760870
[TBL] [Abstract][Full Text] [Related]
19. Maintenance Chemotherapy With Chinese Herb Medicine Formulas vs. With Placebo in Patients With Advanced Non-small Cell Lung Cancer After First-Line Chemotherapy: A Multicenter, Randomized, Double-Blind Trial.
Wang Q; Jiao L; Wang S; Chen P; Bi L; Zhou D; Yao J; Li J; Chen Z; Jia Y; Zhang Z; Shen W; Zhu W; Xu J; Gao Y; Gong Y; Xu L
Front Pharmacol; 2018; 9():1233. PubMed ID: 30459612
[No Abstract] [Full Text] [Related]
20. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.
Brahmer J; Reckamp KL; Baas P; Crinò L; Eberhardt WE; Poddubskaya E; Antonia S; Pluzanski A; Vokes EE; Holgado E; Waterhouse D; Ready N; Gainor J; Arén Frontera O; Havel L; Steins M; Garassino MC; Aerts JG; Domine M; Paz-Ares L; Reck M; Baudelet C; Harbison CT; Lestini B; Spigel DR
N Engl J Med; 2015 Jul; 373(2):123-35. PubMed ID: 26028407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
